At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled Trial of Pentoxifylline Plus Combination ART vs. Combination ART Alone to Improve Endothelial Dysfunction in HIV-Infected Patients
In Brief
A Phase 2 clinical trial evaluating Combination antiretroviral therapy (cART), Pentoxifylline, and 1 other intervention for HIV and 4 related conditions. Completed, enrolled 19 participants across 1 site.
Detailed Summary
People infected with HIV have a greater risk of developing cardiovascular disease than people not infected with HIV. This may be due to increased inflammation in the blood vessels. This study will determine whether an anti-inflammatory drug, pentoxifylline, in combination with antiretroviral medications, is more effective at improving blood vessel function and reducing inflammation than antiretroviral medications alone in people infected with HIV.
Study Details
Timeline
Interventions
Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
Participants will receive placebo three times per day for 48 weeks.